ENGENE THERAPEUTICS INC
ENGNNASDAQTrading Snapshot
- Day Range
- $1.93 – $1.99
- 52-Week Range
- $1.40 – $12.25
- Volume
- $2.24B
- Avg Volume
- $1.57B
- Shares Outstanding
- 67.0M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $13M
- Last Q Revenue
- $3M
- P/E Ratio
- -6.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.07
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +13.7%
Why Investors Own ENGN
- ✓High-growth profile — revenue up +7.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 68% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ENGENE THERAPEUTICS INC
ENGN
StockOtter · stockotter.spaceAbout ENGENE THERAPEUTICS INC
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter e
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the follow
Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable pat